IgG4-Related Disease: The Chameleon Condition That Mimics Cancer, Autoimmune Disease, and Infection Across Multiple Organs

Research-informed explainer — last updated April 12, 2026

IgG4-related disease is a systemic fibroinflammatory condition that can affect virtually any organ — pancreas, salivary glands, bile ducts, kidneys, orbits, aorta, and others — producing masses that look exactly like cancer on imaging until biopsy reveals a characteristic pattern of IgG4-positive plasma cell infiltration. Glucocorticoids produce rapid, dramatic responses in most patients, and rituximab now offers a steroid-sparing option for those who relapse or cannot taper steroids.

This article draws on research by Arezou Khosroshahi, MD, Assistant Professor of Medicine at Emory University School of Medicine, who is one of the foremost authorities on IgG4-RD in the United States: she co-authored the 2019 ACR/EULAR classification criteria (716 citations), published on the diagnostic utility of serum IgG4 concentrations (530 citations), led the first report of rituximab producing rapid IgG4 serum decline and clinical improvement in IgG4-related systemic disease (520 citations), was first author on the rituximab treatment review (486 citations), and published the clinical overview of IgG4-related systemic disease that helped introduce the condition to practicing rheumatologists (332 citations); and Cory Perugino, DO, at Massachusetts General Hospital, who was first author on the international cohort study defining four clinical phenotypes of IgG4-RD (394 citations), first author on the Nature Reviews Rheumatology pathophysiology update (393 citations), first author on the discovery of galectin-3 as an autoantigen (177 citations), and first author on large vessel IgG4-RD (171 citations). Eli Miloslavsky, MD, also at Massachusetts General Hospital, contributes systemic autoimmune disease expertise that informs the differential diagnosis and treatment framework.

What is IgG4-related disease?

IgG4-RD is a recently recognized immune-mediated condition characterized by three pathological hallmarks when tissue is biopsied:

1. Dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells
2. Storiform (whorled) fibrosis
3. Obliterative phlebitis (inflammation that obliterates venous channels)

The condition was first recognized as a unified entity only in the early 2000s, when Japanese researchers noticed that patients with autoimmune pancreatitis, sclerosing cholangitis, and Mikulicz disease (swollen salivary and lacrimal glands) shared these pathological features and elevated serum IgG4. It has since been recognized in virtually every organ system.

Who gets it and where does it appear?

IgG4-RD predominantly affects middle-aged to elderly men — the male-to-female ratio is approximately 3:1, though this varies by organ. Dr. Perugino's analysis of two international cohorts (394 citations) identified four distinct clinical phenotypes:

1. Pancreato-hepato-biliary: pancreas, bile ducts, liver — the most common phenotype in Japan; includes autoimmune pancreatitis (which mimics pancreatic cancer) and IgG4-related sclerosing cholangitis (which mimics cholangiocarcinoma)
2. Retroperitoneal fibrosis and aortitis: kidney, aorta, periaortic tissue — large vessel IgG4-RD (171 citations from Dr. Perugino) can present as periaortic inflammation on FDG-PET before mass lesions develop
3. Head and neck limited: salivary glands, lacrimal glands, orbits, thyroid, meninges
4. Classic Mikulicz with systemic involvement: bilateral salivary and lacrimal swelling combined with other organs

Why it looks like cancer — and how to tell the difference

The most dangerous mimicry is pancreatic cancer. A pancreatic mass, obstructive jaundice, weight loss, and elevated CA19-9 can prompt an urgent Whipple procedure — when the histology actually shows IgG4-RD, which responds completely to prednisone. Dr. Khosroshahi's clinical overview (332 citations) emphasized that clinicians need to recognize the constellation: older male patient, multiple organ involvement, elevated serum IgG4, and a mass that appears relatively homogeneous on CT rather than having the irregular, infiltrating features of adenocarcinoma.

Other conditions commonly mistaken for IgG4-RD:

• Lymphoma (biliary, salivary, orbital masses)
• Sjögren's syndrome (salivary/lacrimal involvement)
• Primary sclerosing cholangitis
• Retroperitoneal fibrosis from other causes
• Orbital pseudotumor
• Wegener's/GPA (orbital and sinus involvement)

The diagnostic utility — and limitations — of serum IgG4

Dr. Khosroshahi's serum IgG4 study (530 citations) provided the most rigorous assessment of this test's performance. Elevated serum IgG4 (above 135 mg/dL) had only about 90% specificity and 60–70% sensitivity for IgG4-RD in a referral population. Approximately 10% of patients with pathologically confirmed IgG4-RD have normal serum IgG4. Conversely, other conditions — including various cancers, inflammatory conditions, and even healthy individuals — can have mildly elevated IgG4. A serum IgG4 level more than four times the upper limit of normal has higher specificity but still does not replace biopsy. Biopsy with IgG4 immunohistochemistry remains the diagnostic gold standard.

The 2019 classification criteria

The ACR/EULAR classification criteria (716 citations), co-authored by Dr. Khosroshahi, introduced a weighted scoring system using three domains: (1) characteristic histopathology and immunostaining on biopsy; (2) characteristic radiologic features by organ; and (3) serology (IgG4 level) and other labs. Points are assigned from each domain and subtracted when mimicking conditions are present. A threshold score of 20 classifies a patient as having IgG4-RD with high specificity. This framework helps ensure consistent enrollment in clinical trials and reduces misclassification.

The autoantigen discovery: galectin-3

Dr. Perugino's 2018 paper (177 citations) identified galectin-3 — a lectin involved in fibrosis and inflammation — as a target autoantigen in IgG4-RD patients. This discovery suggests that IgG4-RD may not simply be a disease of IgG4 antibody excess but involves specific adaptive immune responses against defined self-proteins, opening potential therapeutic targets.

Pathophysiology: T follicular helper cells and B cells

Dr. Perugino's Nature Reviews Rheumatology update (393 citations) describes how activated T follicular helper cells and cytotoxic T cells drive the fibroblast activation and plasma cell accumulation that characterize IgG4-RD. IgG4 itself — an anti-inflammatory, non-complement-fixing subclass — may be a bystander or even a regulatory response rather than the pathogenic agent. This understanding explains why B-cell depletion with rituximab is so effective.

Treatment: steroids first, rituximab for relapse or steroid dependence

First-line: Prednisone 30–40 mg daily tapered over 3–6 months. Response rates are 80–90% across organ systems; clinical improvement within weeks is typical. Serum IgG4 levels typically fall with treatment, though they do not normalize in all patients.

Relapse: Common — occurs in 30–60% of patients after steroid taper. Dr. Khosroshahi's rituximab study (520 citations) documented prompt clinical improvement and a steep decline in serum IgG4 within weeks of two rituximab infusions (1000 mg, 15 days apart), substantially steeper than what is observed in rheumatoid arthritis or other B-cell-mediated diseases. The companion paper (486 citations) in 10 patients showed that all could taper to prednisone discontinuation after rituximab.

Steroid-sparing agents: Azathioprine, mycophenolate, and methotrexate are used in patients who cannot taper steroids, but responses are less reliable than rituximab. Traditional DMARDs are generally considered less effective in IgG4-RD than in RA.

Fibrotic lesions: Advanced fibrosis, particularly retroperitoneal fibrosis or aortic involvement, may not respond to immunosuppression once established; surgical or endovascular intervention may be required for mechanical complications.

Questions to ask your doctor

• Has a biopsy been performed with IgG4 immunostaining, and did it show the characteristic histological features?
• Is my serum IgG4 elevated, and has the diagnosis been confirmed despite the limitations of that test?
• How many organ systems appear to be involved on imaging?
• Is cancer, lymphoma, or infection adequately excluded before starting treatment?
• After steroid induction, what is the plan for maintenance — and is rituximab being considered given my risk of relapse?
• Is my case complex enough to warrant evaluation at a center with specific IgG4-RD expertise?

The bottom line

IgG4-related disease is a systemic fibroinflammatory condition that was barely recognized before 2003 but is now diagnosed in patients whose masses were previously being biopsied for cancer. Glucocorticoids produce dramatic responses in most patients; rituximab effectively induces B-cell depletion for relapsing or steroid-dependent disease. The key to diagnosis is always biopsy — serum IgG4 elevation is supportive but not sufficient on its own.